Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

58.88 USD +0.32 (+0.55%)
Official Closing Price Updated: 7:43 PM EDT, Oct 23, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Arrowhead Pharma

< Previous 1 2 3 4 5 6 7 8 9 Next >
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead reports inducement grants 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results
Arrowhead hosts webcast to discuss Fiscal Year End 2018 results 
From Business Wire News Releases
Detailed Research: Economic Perspectives on Arrowhead Pharmaceuticals, NexGen Energy, ArcBest, Cigna, The Allstate, and Comtech Telecommunications — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arrowhead Pharmaceuticals,... 
From GlobeNewswire News Releases
Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results
Arrowhead Pharmaceuticals to webcast fiscal 2018 year end earnings call on December 11, 2018 
From Business Wire News Releases
Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018
Arrowhead Pharmaceuticals announced clinical data from a Phase 1 study of ARO-AAT at The AASLD Liver Meeting 
From Business Wire News Releases
Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018
Arrowhead Pharmaceuticals announced preliminary clinical data from a Phase 1/2 study (AROHBV1001) of ARO-HBV at the AASLD Liver Meeting 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences
Arrowhead Pharma is presenting at November 2018 conferences 
From Business Wire News Releases
Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen
Arrowhead and Janssen announce closing of license agreement and research collaboration and option agreement 
From Business Wire News Releases
Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A — Emerging Consolidated E
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of IAC/InterActiveCorp... 
From GlobeNewswire News Releases
Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
Arrowhead hosts R&D Day to discuss its emerging pipeline of RNAi therapeutics that leverage the Targeted RNAi Molecule (TRiM™) platform 
From Business Wire News Releases
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Arrowhead filed an application to begin a Phase 1 clinical trial of ARO-ANG3, RNAi-based investigational medicine for the treatment of dyslipidemias. 
From Business Wire News Releases
Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will make two late-breaking poster presentations at The AASLD Liver Meeting® 2018 
From Business Wire News Releases
Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
Arrowhead and Janssen sign $3.7 billion license agreement for RNAi therapeutics against hepatitis B virus and 3 additional targets 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
Arrowhead Pharmaceuticals will present at upcoming October 2018 conferences 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
Arrowhead Pharmaceuticals will host an R&D day on September 24, 2018 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) 
From Business Wire News Releases
Thinking about buying stock in Arrowhead Research, Facebook, Marvell Technology, Nike or Pretium Resources?
InvestorsObserver issues critical PriceWatch Alerts for ARWR, FB, MRVL, NKE, and PVG. 
From PR Newswire
Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
Arrowhead presents initial clinical data for ARO-HBV at the 18th World Gastroenterologists Summit in Auckland, New Zealand. 
From Business Wire News Releases
Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharma completes dosing in Phase 1 study of ARO-AAT 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences
Arrowhead will present at multiple September 2018 conferences 
From Business Wire News Releases
New Research Coverage Highlights MACOM Technology Solutions, Arrowhead Pharmaceuticals, PTC Therapeutics, Boot Barn, Darling Ingredients, and Endologix — Consolidated Revenues, Company Growth, and Exp
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MACOM Technology Solutions... 
From GlobeNewswire News Releases
Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results
Arrowhead announced financial results for its fiscal 2018 third quarter ended June 30, 2018 
From Business Wire News Releases
Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
Arrowhead Pharmaceuticals earned a $10 million milestone payment from Amgen after the first dose of AMG 890, formerly ARO-LPA, in a clinical study 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Third Quarter Results
Arrowhead Pharmaceuticals will webcast its fiscal 2018 third quarter earnings report 
From Business Wire News Releases
Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
Arrowhead presents preclinical and clinical data on ARO-AAT, for treatment of alpha-1 liver disease, at the Alpha-1 National Education Conference 
From Business Wire News Releases
Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency 
From Business Wire News Releases
Investor Expectations to Drive Momentum within AMC Entertainment, Arrowhead Pharmaceuticals, U.S. Silica, Catalent, RSP Permian, and KapStone Paper and Packaging — Discovering Underlying Factors of In
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMC Entertainment Holdings,... 
From GlobeNewswire News Releases
Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals completed enrollment of a Phase 1 clinical study of ARO-AAT for treatment of alpha-1 antitrypsin deficiency 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) 
From Business Wire News Releases
Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
Arrowhead Pharmaceuticals completed enrollment and dosing of the single-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV. 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.